The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Tarceva     N-(3-ethynylphenyl)-6,7- bis(2...

Synonyms: erlotinib HCl, OSI-774, S1023_Selleck, Tarceva (OSI), Bio-0036, ...
This record was replaced with 176870.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Tarceva


High impact information on Tarceva

  • In addition, they predicted for therapeutic synergy of OSI-774 and Herceptin as well as for drug resistance [3].
  • The pharmacokinetics of OSI-774 and its O-demethylated metabolite, OSI-420, were characterized [2].
  • Part B patients received OSI-774 doses ranging from 50 to 200 mg given once daily for 3 weeks every 4 weeks to establish the maximum tolerated dose (MTD) [2].
  • Only changes in p27 expression were related to the administered dose of OSI-774 [6].
  • There was a significant decrease in phospho-EGFR (Tyr 1173) expression as determined semiquantitatively with OSI-774 treatment [2.75 +/- 0.51 (mean +/- SD) pretreatment versus 2.36 +/- 0.76 after treatment, pair comparison P = 0.01] [6].

Chemical compound and disease context of Tarceva


Biological context of Tarceva


Anatomical context of Tarceva

  • In conclusion, the combination treatment of ART and OSI-774 resulted in an increased growth inhibition of GBM cell lines as compared to each drug alone [7].
  • RESULTS: IC(50) values for GEO, FET, and HCT 116 cell lines exposed to OSI-774 were 12.0, 16.0, and greater than 100 mum, respectively [11].

Associations of Tarceva with other chemical compounds

  • The anti-malarial artesunate (ART) and the EGFR tyrosine kinase inhibitor OSI-774 reveal profound cytotoxic activity [7].
  • Some of these agents, such as ZD1839 and OSI-774, tend to bind in vitro only to the epidermal growth factor receptor tyrosine kinase while others, such as CI-1033, bind to multiple members of the ErbB family [12].
  • A high-performance liquid-chromatographic (HPLC) assay with UV detection has been developed for the quantitative determination of erlotinib (OSI-774) in human plasma [13].
  • Low-molecular-weight inhibitors of the EGFR tyrosine kinase also in clinical development include OSI-774, PD182905, PKI-166, CI-1033, and ZD1839 [14].
  • Although wortmannin failed to enhance gemcitabine-induced apoptosis in OCIP#7 tumors, the extent of apoptosis was significantly increased with the inclusion of OSI-774 in the combination [8].

Gene context of Tarceva


Analytical, diagnostic and therapeutic context of Tarceva


  1. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Lal, A., Glazer, C.A., Martinson, H.M., Friedman, H.S., Archer, G.E., Sampson, J.H., Riggins, G.J. Cancer Res. (2002) [Pubmed]
  2. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Hidalgo, M., Siu, L.L., Nemunaitis, J., Rizzo, J., Hammond, L.A., Takimoto, C., Eckhardt, S.G., Tolcher, A., Britten, C.D., Denis, L., Ferrante, K., Von Hoff, D.D., Silberman, S., Rowinsky, E.K. J. Clin. Oncol. (2001) [Pubmed]
  3. Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Reyzer, M.L., Caldwell, R.L., Dugger, T.C., Forbes, J.T., Ritter, C.A., Guix, M., Arteaga, C.L., Caprioli, R.M. Cancer Res. (2004) [Pubmed]
  4. The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Perez-Soler, R. Clin. Cancer Res. (2004) [Pubmed]
  5. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Townsley, C.A., Major, P., Siu, L.L., Dancey, J., Chen, E., Pond, G.R., Nicklee, T., Ho, J., Hedley, D., Tsao, M., Moore, M.J., Oza, A.M. Br. J. Cancer (2006) [Pubmed]
  6. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Malik, S.N., Siu, L.L., Rowinsky, E.K., deGraffenried, L., Hammond, L.A., Rizzo, J., Bacus, S., Brattain, M.G., Kreisberg, J.I., Hidalgo, M. Clin. Cancer Res. (2003) [Pubmed]
  7. Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Efferth, T., Ramirez, T., Gebhart, E., Halatsch, M.E. Biochem. Pharmacol. (2004) [Pubmed]
  8. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Ng, S.S., Tsao, M.S., Nicklee, T., Hedley, D.W. Mol. Cancer Ther. (2002) [Pubmed]
  9. Development of the epidermal growth factor receptor inhibitor OSI-774. Grünwald, V., Hidalgo, M. Semin. Oncol. (2003) [Pubmed]
  10. Signal transduction inhibitors in the treatment of breast cancer. Nahta, R., Hortobagyi, G.N., Esteva, F.J. Current medicinal chemistry. Anti-cancer agents. (2003) [Pubmed]
  11. Compensatory Increases in Her-2/neu Activation in Response to EGFR Tyrosine Kinase Inhibition in Colon Cancer Cell Lines. Learn, P.A., Krishnegowda, N., Talamantez, J., Kahlenberg, M.S. J. Surg. Res. (2006) [Pubmed]
  12. Small-molecule tyrosine kinase inhibitors as radiosensitizers. Lawrence, T.S., Nyati, M.K. Seminars in radiation oncology. (2002) [Pubmed]
  13. Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. Lepper, E.R., Swain, S.M., Tan, A.R., Figg, W.D., Sparreboom, A. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2003) [Pubmed]
  14. Growth factors and their receptors: new targets for prostate cancer therapy. Barton, J., Blackledge, G., Wakeling, A. Urology (2001) [Pubmed]
  15. Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. Halatsch, M.E., Gehrke, E.E., Vougioukas, V.I., Bötefür, I.C., A-Borhani, F., Efferth, T., Gebhart, E., Domhof, S., Schmidt, U., Buchfelder, M. J. Neurosurg. (2004) [Pubmed]
  16. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Higgins, B., Kolinsky, K., Smith, M., Beck, G., Rashed, M., Adames, V., Linn, M., Wheeldon, E., Gand, L., Birnboeck, H., Hoffmann, G. Anticancer Drugs (2004) [Pubmed]
  17. OSI-774 OSI Pharmaceuticals. Norman, P. Current opinion in investigational drugs (London, England : 2000) (2001) [Pubmed]
  18. Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection. Zhang, W., Siu, L.L., Moore, M.J., Chen, E.X. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2005) [Pubmed]
WikiGenes - Universities